In the current study, we used a 27-gene panel assay to: (i) identify additional prognostically-relevant mutations in CMML, (ii) to determine if the number of mutations carries prognostic relevance and (iii) to study the prognostic interplay between TET2 and ASXL1 mutations. Here, ASXL1 is linked to chronic myelomonocytic leukemia.